CN101979555B - Small interference RNA molecule and application thereof - Google Patents
Small interference RNA molecule and application thereof Download PDFInfo
- Publication number
- CN101979555B CN101979555B CN201010521975.0A CN201010521975A CN101979555B CN 101979555 B CN101979555 B CN 101979555B CN 201010521975 A CN201010521975 A CN 201010521975A CN 101979555 B CN101979555 B CN 101979555B
- Authority
- CN
- China
- Prior art keywords
- hbv
- sirna
- hepatitis
- gene
- company
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a small interference RNA molecule and application thereof. The sense strand of the small interference RNA molecule is SEQ ID No: 3, while the antisense strand is SEQ ID No: 4, wherein the antisense strand can be specifically combined with mRNA of an HBV (hepatitis B virus) polymerase gene to degrade the mRNA so as to interfere with the translation process after transcription and fulfill the purpose of resisting hepatitis B viruses.
Description
Technical field
The present invention relates to a kind of siRNA molecule and application thereof.
Background technology
Hepatitis, i.e. inflammation, there is multiple paathogenic factor-as virus, bacterium, parasite, chemical toxicant, medicine and poisonous substance, alcohol etc., infringement liver, the cell of liver is damaged, the function of liver suffers damage, and it can cause a series of malaise symptoms of health, and the exception of liver function index.Hepatitis in most cases refers to it is the viral hepatitis caused by A type, B-mode, the hepatitis virus such as the third type, fourth type, penta type.
Hepatitis B virus (Hepatitis B virus, HBV) hepatitis B caused is infected, be a kind of serious threat global human health communicable disease, also be the viral hepatitis of most serious types, it can cause chronic hepatopathy, and the risk that patient dies from liver cirrhosis and liver cancer is high.
HBV belongs to Hepadnaviridae (Hepadnaviridae), and full-length genome is about 3.2kb, is partially double stranded cyclic DNA.Its genome has four open reading frame (Open Reading Frame, ORF), proteins encoded comprises surface antigen (S gene), cAg (C gene), polymerase protein (P gene) and X protein (C gene).
According to World Health Organization, the whole world estimates at 2,000,000,000 people and infects HBV, wherein has the artificial chronic hepatitis B infections person of more than 3.5 hundred million, and estimating has 600,000 people to die from acute or chronic hepatitis B every year.HBV can cause acute sufferer, symptom sustainable several weeks, comprises skin and eyes jaundice (jaundice), and urine color depth is extremely tired, feels sick, vomiting and stomachache.Patient may need several months and even 1 year ability recovery from illness.Hepatitis B virus also can cause chronic liver infection, may develop into liver cirrhosis or liver cancer later.
In interpersonal propagation, route of transmission is identical with human immunodeficiency virus (virus of AIDS) by contacting with the blood or other body fluid (such as, seminal fluid and vaginal secretions) of sufferer for hepatitis B virus.The infectivity of hepatitis B virus is stronger than virus of AIDS 50-100 times, and hepatitis B virus can survive more than at least 7 days in vitro.During this period, if the health of the non-the infected of cell entry, it still can cause infection.Virus latency average out to 90 days, but also may be about 30 to 180 days not etc.Hepatitis B virus can find after infection for 30 to 60 days, and time length difference is very large.
Mainly prevented the generation of hepatitis B at present by baby's Hepatitis B Immunization, however, crowd HBV prevalence rate is still very high.The method of current primary treatment chronic hepatitis B is only confined to suppress the expression of patient body inner virus gene and copy.As oral ucleosides antiviral drug-lamivudine, major function suppresses copying of HBV, but recurrence rate is high after drug withdrawal, prolonged application then can cause virus variation, occur after 6 months to be morphed the resistance caused by varial polymerases gene in medication, make clinical antiviral therapy face great challenge.
In recent years, along with RNA disturbs the fast development of (RNAi) technology, for disease especially cancer opens brand-new therapy approach, for researcher provides a brand-new gene therapy method.This technology is by disturbing the expression of particular target gene with siRNA (small interfering RNA, siRNA), reaching the object of disease therapy, is the important component part of gene therapy.RNA interference (RNA interference, RNAi) is the PTGS mechanism caused by double-stranded RNA (double-stranded RNA, dsRNA).Its mechanism of action is: the Dicer enzyme of rnase iii family, be combined with dsRNA, cut into the siRNA that 21-23nt and 3 ' distal process goes out, siRNA and RNA induces silencing complex (RNA-induced silencing complex subsequently, RISC) combine, untwist into strand, the RISC of activation is by becoming the siRNA of strand to guide, be attached to target messenger RNA(mRNA) (mRNA) go up and cut off sequence-specific, cause the specific cleavage of said target mrna, thus block corresponding gene expression.RNAi, as a kind of technology of simple and effective gene knockout, is widely used in the research of functional genomics research and antiviral, antineoplaston.
The invention provides a kind of method that RNAi technology carrys out Anti-HBV activity.Application RNA perturbation technique, with target to the siRNA of HBV gene as targeted drug, disturb after the transcribing of gene, thus effectively suppress protein expression and the virus replication of HBV, there is the advantage of high specificity, efficient, little, the sustainable medication of side effect, and the deficiency for the treatment of hepatitis B medicament at present can be made up, a kind of method for the treatment of hepatitis B newly may be become in the near future.
Summary of the invention
The object of the present invention is to provide a kind of Double-stranded siRNA molecules of the efficient target HBV gene gone out by siRNA whole site molecule library technology screening, its following positive-sense strand and antisense strand composition:
Positive-sense strand: 5 '-UUGAAGUCCCAAUCUGGAUNN-3 ' (SEQ ID NO:3)
Antisense strand: 5 '-AUCCAGAUUGGGACUUCAANN-3 ' (SEQ ID NO:4)
Wherein, N is any one of A, T, C, G or U base.
In other words, the backbone sequences of this Double-stranded siRNA molecules is:
Positive-sense strand: 5 '-UUGAAGUCCCAAUCUGGAU-3 ' (SEQ ID NO:5)
Antisense strand: 5 '-AUCCAGAUUGGGACUUCAA-3 ' (SEQ ID NO:6)
In one preferred embodiment, in above-mentioned sequence, 3 ' " NN " held is two deoxythymidine dTdT.
Another object of the present invention is to provide above-mentioned siRNA molecule preparing the application in Anti-HBV drugs.
Experiment in vitro proves, the antisense strand of siRNA molecule of the present invention can be combined with the mRNA of HBV pol gene specifically, degraded mRNA, thus rear translation process is transcribed in interference, suppresses HBV protein translation and virus replication, reaches the therapeutic purpose of Anti-HBV activity.
Accompanying drawing explanation
Fig. 1 is the HBV gene group agarose gel electrophoresis detection figure of extracting.M is 1kb plus DNA Ladder (standard reference).
Fig. 2 A HBV polymerase fragment 1 agarose gel electrophoresis detects figure, and the DNA fragmentation size prepared is 1625bp.Fig. 2 B is HBV polymerase fragment 2 agarose gel electrophoresis detection figure, and the DNA fragmentation size prepared is 874bp.M is 1kb plus DNA Ladder (standard reference).
Fig. 3 is that siRNA molecule storehouse builds schematic flow sheet.
Fig. 4 is U6-siRNA transcription templates-H1 expression cassette structural representation.
Fig. 5 is agarose gel electrophoresis detection figure after the U6-siRNA transcription templates-H1 expression cassette purifying prepared of PCR.In figure, M is 1kb plus DNA Ladder (standard reference); 1 is HBV-22; 2 is HBV-676; 3 is HBV-877; 4 is HBV-638; 5 is HBV-1003; 6 is HBV-748; 7 is HBV-182; 8 is HBV-261; 9 is negative control.
Fig. 6 is that after expression cassette transfectional cell, real-time quantitative PCR detects HBV pol gene mrna expression amount column diagram, and ordinate zou represents HBV pol gene mrna expression level; X-coordinate represents process experimental group, and " Negative Control " is negative control group.
Embodiment
In the present invention, such as the term such as " siRNA ", " siRNA sequence " or " siRNA molecule " can exchange, and its meaning represented is identical with scope.
Wherein, siRNA sequence can be single-stranded structure, also can be duplex structure.
The siRNA molecule storehouse that siRNA molecule of the present invention derives from the function conserved regions for HBV pol gene and prepares, the present invention's siRNA whole site molecule library used technology is that (Chinese invention patent number is: ZL 200710024217.6 for the patented technology of Biomics Bioisystech Co., Ltd, patent name: PCR high flux construction siRNA whole site molecule library preparation method), its advantage is that preparation-obtained siRNA is randomly distributed in HBV pol gene section, length controllability is distributed in 18-25bp, can improve the hit rate of effective target site.
The preparation of siRNA can adopt multiple method, such as: chemical synthesis, in-vitro transcription, enzyme cut long-chain dsRNA, vector expression siRNA, PCR synthesize siRNA Expression element etc., the investigator that appears as of these methods provides selectable space, can obtain gene silencing efficiency better.
SiRNA molecule of the present invention can as the effective constituent of Anti-HBV drugs.
As the another kind of expression-form of this siRNA molecule, DNA expression cassette form can be prepared into, such as: U6 promotor-siRNA transcription templates-H1 promotor.
In brief, hereinafter " U6 promotor-siRNA transcription templates-H1 promotor " is abbreviated as " U6-siRNA transcription templates-H1 " or " U6-siRNA-H1 ", the meaning that they represent is identical with scope.
For application purpose, can siRNA molecule, the DNA expression cassette of expressing siRNA molecule or the plasmid comprising siRNA molecule expression cassette directly be delivered medicine to by medicine person privileged site with it as medicine, such as lesion tissue.
The formulation of medicine of the present invention can be various ways, as long as be suitable for the administration of corresponding disease and keep the activity of siRNA molecule rightly.Such as, for injection drug delivery system, formulation can be lyophilized powder.
Optionally, the acceptable auxiliary of any pharmacy in said medicine formulation, can be comprised, as long as it is suitable for corresponding drug delivery system and keep the activity of siRNA molecule rightly.
In order to realize design philosophy of the present invention and verify the Anti-HBV activity effect of screening the siRNA obtained, devise following experimental program:
(1) build the siRNA molecule storehouse of HBV pol gene, comprise the siRNA effector molecule of target to HBV pol gene in this library of molecules, length distribution is in 18-25bp.
(2) preparation has the siRNA expression cassette of respective effects, and its structure is U6 promotor-siRNA transcription templates-H1 promotor, makes it be easier to in-vitro screening.
(3) use Real-time quantitative PCR, detect effect siRNA molecule that above-mentioned siRNA expression cassette records out at transit cell to the restraining effect of HBV pol gene.
Following embodiment only for illustrating the present invention, not limits the invention.
Embodiment 1
The preparation of siRNA whole site molecule library
1. key instrument, reagent and material
1.1 instruments: PCR instrument (ABI company); Electroporation (Bio-Rad company); Whizzer (Eppendorf company), long wavelength ultraviolet lamp etc.
1.2 materials and reagent: HepG22.2.15 cell (hundred Ao Maike companies preserve); 1kb plus DNA Ladder (invitrogen company); DNaseI (Roche company); MnCl
2(BBI company); Phospholinker (Sigma-aldrich company); ATP (BBI company); BSA (NEB company); BmsbI (NEB company); T4DNA ligase enzyme (NEB company); Tag archaeal dna polymerase (hundred Ao Maike companies); Agarose (BBI company); DNTP (the raw work in Shanghai); Phenol chloroform reagent (the raw work in Shanghai); Low-molecular-weight dna Ladder (NEB company); EcoP15I (NEB company); T4DNA polysaccharase (NEB company); FokI enzyme (NEB company); SfiI enzyme (NEB company); Competent cell (invitrogen company); PU6H1-GFP expression vector (NT Oimcs company).Gel extraction agent box: QIAEX II Gel Extration Kit (QIAGEN company); Plasmid extraction test kit (hundred Ao Maike companies).Other biochemical reagents are all purchased from Sigma-aldrich company.
The structure of 2.siRNA whole site molecule library
The acquisition of 2.1HBV pol gene: pcr amplification HBV polymerase fragment from the genomic dna (as shown in Figure 1) of cell HepG22.2.15.HepG22.2.15 cell is containing the HBV gene group of 2 copies, energy stably excreting HBsAg, HBeAg, HBcAg and Dane particle, and intermediate duplication body (Sells et al.Proc Natl Acad Sci, 1987 such as DNA and RNA of HBV in cell can be detected; 84:1005-1009), its blood serum subtype containing HBV is ayw (GenBank Accession number:U95551), according to the nucleotide sequence design pcr amplification primer of GenBank report, being divided into two fragments is HBV polymerase fragment 1 and HBV polymerase fragment 2, and length is respectively: 1625bp (as shown in Figure 2 A) and 874bp (as shown in Figure 2 B).Primer sequence is as follows:
HBV polymerase fragment 1 upstream primer: 5 '-AATTCCACAACCTTTCACCAA-3 ';
HBV polymerase fragment 1 downstream primer: 5 '-TCACGGTGGTCTCCATGCGA-3 ';
HBV polymerase fragment 2 upstream primer: 5 '-ATGCCCCTATCCTATCAACAC-3 ';
HBV polymerase fragment 2 downstream primer: 5 '-CCACTGCATGGCCTGAGGAT-3 '.
1) HBV polymerase fragment 1 sequence:
1 aattccacaa cctttcacca aactctgcaa gatcccagag tgagaggcct gtatttccct
61 gctggtggct ccagttcagg agcagtaaac cctgttccga ctactgcctc tcccttatcg
121 tcaatcttct cgaggattgg ggaccctgcg ctgaacatgg agaacatcac atcaggattc
181 ctaggacccc ttctcgtgtt acaggcgggg tttttcttgt tgacaagaat cctcacaata
241 ccgcagagtc tagactcgtg gtggacttct ctcaattttc tagggggaac taccgtgtgt
301 cttggccaaa attcgcagtc cccaacctcc aatcactcac caacctcctg tcctccaact
361 tgtcctggtt atcgctggat gtgtctgcgg cgttttatca tcttcctctt catcctgctg
421 ctatgcctca tcttcttgtt ggttcttctg gactatcaag gtatgttgcc cgtttgtcct
481 ctaattccag gatcctcaac caccagcacg ggaccatgcc gaacctgcat gactactgct
541 caaggaacct ctatgtatcc ctcctgttgc tgtaccaaac cttcggacgg aaattgcacc
601 tgtattccca tcccatcatc ctgggctttc ggaaaattcc tatgggagtg ggcctcagcc
661 cgtttctcct ggctcagttt actagtgcca tttgttcagt ggttcgtagg gctttccccc
721 actgtttggc tttcagttat atggatgatg tggtattggg ggccaagtct gtacagcatc
781 ttgagtccct ttttaccgct gttaccaatt ttcttttgtc tttgggtata catttaaacc
841 ctaacaaaac aaagagatgg ggttactctc tgaattttat gggttatgtc attggaagtt
901 atgggtcctt gccacaagaa cacatcatac aaaaaatcaa agaatgtttt agaaaacttc
961 ctattaacag gcctattgat tggaaagtat gtcaacgaat tgtgggtctt ttgggttttg
1021 ctgccccatt tacacaatgt ggttatcctg cgttaatgcc cttgtatgca tgtattcaat
1081 ctaagcaggc tttcactttc tcgccaactt acaaggcctt tctgtgtaaa caatacctga
1141 acctttaccc cgttgcccgg caacggccag gtctgtgcca agtgtttgct gacgcaaccc
1201 ccactggctg gggcttggtc atgggccatc agcgcgtgcg tggaaccttt tcggctcctc
1261 tgccgatcca tactgcggaa ctcctagccg cttgttttgc tcgcagcagg tctggagcaa
1321 acattatcgg gactgataac tctgttgtcc tctcccgcaa atatacatcg tatccatggc
1381 tgctaggctg tgctgccaac tggatcctgc gcgggacgtc ctttgtttac gtcccgtcgg
1441 cgctgaatcc tgcggacgac ccttctcggg gtcgcttggg actctctcgt ccccttctcc
1501 gtctgccgtt ccgaccgacc acggggcgca cctctcttta cgcggactcc ccgtctgtgc
1561 cttctcatct gccggaccgt gtgcacttcg cttcacctct gcacgtcgca tggagaccac
1621 cgtga(SEQ ID NO：1)
2) HBV polymerase fragment 2 sequence:
2281 at gcccctatcc tatcaacact tccggaaact
2341 actgttgtta gacgacgagg caggtcccct agaagaagaa ctccctcgcc tcgcagacga
2401 aggtctcaat cgccgcgtcg cagaagatct caatctcggg aacctcaatg ttagtattcc
2461 ttggactcat aaggtgggga actttactgg tctttattct tctactgtac ctgtctttaa
2521 tcctcattgg aaaacaccat cttttcctaa tatacattta caccaagaca ttatcaaaaa
2581 atgtgaacag tttgtaggcc cacttacagt taatgagaaa agaagattgc aattgattat
2641 gcctgctagg ttttatccaa aggttaccaa atatttacca ttggataagg gtattaaacc
2701 ttattatcca gaacatctag ttaatcatta cttccaaact agacactatt tacacactct
2761 atggaaggcg ggtatattat ataagagaga aacaacacat agcgcctcat tttgtgggtc
2821 accatattct tgggaacaag atctacagca tggggcagaa tctttccacc agcaatcctc
2881 tgggattctt tcccgaccac cagttggatc cagccttcag agcaaacaca gcaaatccag
2941
attgggactt caatcccaac aaggacacct ggccagacgc caacaaggta ggagctggag
3001 cattcgggct gggtttcacc ccaccgcacg gaggcctttt ggggtggagc cctcaggctc
3061 agggcatact acaaactttg ccagcaaatc cgcctcctgc ctccaccaat cgccagacag
3121 gaaggcagcc taccccgctg tctccacctt tgagaaacac tcatcctcag gccatgcagt
3181 gg(SEQ ID NO：2)
2.2siRNA library of molecules builds: (patent No. is: ZL 200710024217.6 to build siRNA molecule storehouse by the patented technology of Biomics Bioisystech Co., Ltd, patent name: PCR high flux construction siRNA whole site molecule library preparation method), build flow process as shown in Figure 3.
Success builds the siRNA molecule storehouse of HBV pol gene, and random picked clones checks order, and its sequence length controllability is distributed between 18-25bp, demonstrates the diversity of site and length.
Embodiment 2
The preparation of siRNA expression cassette and target site screen
1. key instrument, reagent and material
1.1 instruments: PCR instrument (ABI company); Real-time PCR (Bio-Rad company); Gel electrophoresis equipment (Beijing 6 1); Long wavelength ultraviolet lamp; Cell culture incubator (Thermo company) etc.
1.2 materials and reagent: 1kb plus DNA Ladder (invitrogen company); Pfu archaeal dna polymerase (hundred Ao Maike companies); Agarose (BBI company); DNTP (the raw work in Shanghai); Agarose gel purification test kit (hundred Ao Maike companies), Lipofectamin
tM2000 (invitrogen companies), DMEM substratum (Gibco company), TurboCapture mRNA kit (QIAGEN company), SensiMix
tMone-Step Kit (Quantace company) etc.Other biochemical reagents are all purchased from the raw work in Shanghai.
1.3PCR primer (hundred Ao Maike synthesis):
5 ' U6 promoter primer: 5 '-AAGGTCGGGCAGGAAGAGGGC-3 '
3 ' H1 promoter primer: 5 '-TATTTGCATGTCGCTATGTGTTCT-3 '
HBV polysaccharase forward primer: 5 '-TGTGGTTATCCTGCGTTAATG-3 '
HBV polysaccharase reverse primer: 5 '-GCGTCAGCAAACACTTGG-3 '
GAPDH forward primer: 5 '-GAAGGTGAAGGTCGGAGTC-3 '
GAPDH reverse primer: 5 '-GAAGATGGTGATGGGATTTC-3 '
The preparation of 2.siRNA expression cassette
2.1PCR amplification preparation U6-siRNA transcription templates-H1 expression cassette: choosing 8 routine HBV polysaccharase siRNA positive colony plasmids is template, by method amplification preparation U6-siRNA transcription templates-H1 expression cassette (Fig. 3 be expression cassette schematic diagram) of high-fidelity enzyme Pfu archaeal dna polymerase by PCR.
Each PCR reaction system is 50 μ l reaction systems: 0.5 μ l template DNA (10-50ng), 1 μ l 5 ' U6 promoter primer (10 μMs), 1 μ l 3 ' H1 promoter primer (10 μMs), 1 μ l dNTP (10mM), 0.5 μ l Pfu archaeal dna polymerase, uses ddH
2o supplies 50 μ l.Reaction conditions is: 95 DEG C of 1min denaturations, 95 DEG C of 15sec sex change, and 58 DEG C of 30sec annealing, 72 DEG C of 30sec extend, 20 circulations.1.0% agargel electrophoresis detects, and PCR primer band is single, and clip size meets requirement of experiment.
2.2 expression cassette PCR primer purifying: 1.0% agarose gel electrophoresis is separated the expression cassette that obtains of pcr amplification, and with agarose gel purification kits jel product.DNA after purifying carries out 1.0% agarose gel electrophoresis detection again, and the U6-siRNA transcription templates-H1 expression cassette purity after purifying and concentration meet the requirements, as shown in Figure 4.Record the expression cassette concentration after preparation with ultraviolet spectrophotometer simultaneously and be about 200ng/ μ l.
3. target site screening
3.1 cell cultures: hepatocellular carcinoma H22 2.2.15 containing 10%FBS DMEM substratum in, 37 DEG C, 5%CO
2incubator is cultivated.
3.2 plating cells transfection: by cell by 1 × 10
5/ hole is inoculated in 96 porocyte culture plates, in the DMEM substratum of nonreactive containing 10%FBS, and 37 DEG C, 5%CO
2incubator overnight incubation.
Transfection is according to Lipofectamin
tMthe specification sheets transfection of 2000, U6-siRNA transcription templates-H1 expression cassette DNA amount adds by 0.2 μ g/ hole.
3.3 real-time quantitative PCRs detect HBV pol gene mRNA level in-site: with mRNA extraction purification test kit TurboCapture mRNAkit extraction purification cell RNA, operation is undertaken by test kit specification sheets, dissolve RNA with 80 μ l without RNase water/hole, getting 4 μ l RNA is that template carries out real-time quantitative PCR reaction.
Detect HBV pol gene mrna expression level in sample with gene-specific primer, the house-keeping gene GAPDH that simultaneously increases contrasts as internal reference.3 parallel laboratory tests are done in each reaction.Set up the reaction system of following 25 μ l: 4 μ l template ribonucleic acids, 12.5 μ l 2 × SensiMix One-Step, 1 μ l 5 ' forward primer (6 μMs), 1 μ l 3 ' reverse primer (6 μMs), 0.5 μ l 50 × SYBR Green I, supplies system to 25 μ l with without RNase water.Reaction conditions: 42 DEG C of reverse transcription 30min, 95 DEG C of denaturation 7min, 95 DEG C of sex change 20sec, 60 DEG C of annealing 30sec, 72 DEG C extend 30sec, circulate 45 times.
3.4 interpretations of result: with real-time quantitative PCR 2
-Δ Δ ctmethod analysis design mothod result, and make histogram, as shown in Figure 5, the siRNA that result display corresponds to the multiple site of HBV pol gene all presents good silencing efficiency, especially HBV-261, reaches 86% relative to its silencing efficiency of untransfected group.
Especially it should be noted that, HBV-261 sense strand sequence is corresponding with the 2935-2953 position (underscore part atccagattgggacttcaa) of HBV pol gene.
Claims (3)
1. a siRNA molecule, is characterized in that, its sequence is:
Positive-sense strand: 5 '-UUGAAGUCCCAAUCUGGAUNN-3 ' SEQ ID NO:3,
Antisense strand: 5 '-AUCCAGAUUGGGACUUCAANN-3 ' SEQ ID NO:4,
Wherein, N is any one of A, T, C, G or U base.
2. a kind of siRNA molecule as claimed in claim 1, is characterized in that, described N is T.
3. the siRNA molecule according to any one of claim 1 ~ 2 is preparing the application in hepatitis B virus resisting medicine.
Priority Applications (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010521975.0A CN101979555B (en) | 2010-10-28 | 2010-10-28 | Small interference RNA molecule and application thereof |
| PCT/CN2011/081386 WO2012055362A1 (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
| CN201180062884.8A CN103370415B (en) | 2010-10-28 | 2011-10-27 | HBV is treated |
| US13/882,124 US9080174B2 (en) | 2010-10-28 | 2011-10-27 | HBV treatment |
| AU2011320437A AU2011320437B2 (en) | 2010-10-28 | 2011-10-27 | HBV treatment |
| SI201131733T SI3124610T1 (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
| KR1020187027763A KR20180110186A (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
| EP16188642.9A EP3124610B1 (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
| EP11835635.1A EP2633051B1 (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
| RU2013124422A RU2620966C2 (en) | 2010-10-28 | 2011-10-27 | Treatment of hbv infection |
| HUE16188642 HUE044426T2 (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
| TR2019/08127T TR201908127T4 (en) | 2010-10-28 | 2011-10-27 | Hbv therapy. |
| PL16188642T PL3124610T3 (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
| PT16188642T PT3124610T (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
| RS20190704A RS58982B1 (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
| CA2853613A CA2853613C (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
| KR1020137013563A KR101903778B1 (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
| ES16188642T ES2730393T3 (en) | 2010-10-28 | 2011-10-27 | HBV treatment |
| DK16188642.9T DK3124610T3 (en) | 2010-10-28 | 2011-10-27 | HBV TREATMENT |
| BR112013010525A BR112013010525A2 (en) | 2010-10-28 | 2011-10-27 | hbv treatment |
| LTEP16188642.9T LT3124610T (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
| US14/731,824 US9410154B2 (en) | 2010-10-28 | 2015-06-05 | HBV treatment |
| US15/206,948 US9790502B2 (en) | 2010-10-28 | 2016-07-11 | HBV treatment |
| HRP20190995TT HRP20190995T1 (en) | 2010-10-28 | 2019-05-31 | Hbv treatment |
| CY20191100583T CY1121894T1 (en) | 2010-10-28 | 2019-06-03 | HBV TREATMENT |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010521975.0A CN101979555B (en) | 2010-10-28 | 2010-10-28 | Small interference RNA molecule and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101979555A CN101979555A (en) | 2011-02-23 |
| CN101979555B true CN101979555B (en) | 2015-01-21 |
Family
ID=43600095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010521975.0A Active CN101979555B (en) | 2010-10-28 | 2010-10-28 | Small interference RNA molecule and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101979555B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1523113A (en) * | 2003-02-20 | 2004-08-25 | 重庆医科大学 | Construction of hepatitis B virus siRNA expression vector and its application in antivirus treatment |
| CN1648250A (en) * | 2004-12-07 | 2005-08-03 | 浙江大学 | Smal linterference ribonucleic acid sequence of hepatitis B virus gene and preparing method |
| CN101077883A (en) * | 2004-12-07 | 2007-11-28 | 浙江大学 | Small interference RNA sequence of hepatitis B virus gene and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067249B2 (en) * | 2003-05-19 | 2006-06-27 | The University Of Hong Kong | Inhibition of hepatitis B virus (HBV) replication by RNA interference |
-
2010
- 2010-10-28 CN CN201010521975.0A patent/CN101979555B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1523113A (en) * | 2003-02-20 | 2004-08-25 | 重庆医科大学 | Construction of hepatitis B virus siRNA expression vector and its application in antivirus treatment |
| CN1648250A (en) * | 2004-12-07 | 2005-08-03 | 浙江大学 | Smal linterference ribonucleic acid sequence of hepatitis B virus gene and preparing method |
| CN101077883A (en) * | 2004-12-07 | 2007-11-28 | 浙江大学 | Small interference RNA sequence of hepatitis B virus gene and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101979555A (en) | 2011-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3187588B1 (en) | Use of alphavirus in preparation of antitumor drugs | |
| Guo et al. | HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state | |
| US11234968B2 (en) | Use of VCP inhibitor and oncolytic virus in the preparation of an anti-tumor drug | |
| Baldassarre et al. | Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5’UTR of SARS-CoV-2 | |
| Baek et al. | MicroRNA-targeting therapeutics for hepatitis C | |
| CN108929870B (en) | siRNA molecule for inhibiting HBV and application thereof | |
| CN111518886B (en) | MicroRNA related to sorafenib drug resistance of tumor cells and application thereof | |
| Zhang et al. | RNA Interference inhibits hepatitis B virus of different genotypes in vitro and in vivo | |
| Shirvani et al. | Non-coding RNA in SARS-CoV-2: progress toward therapeutic significance | |
| EP2071030A2 (en) | Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus | |
| CN101979556B (en) | Small interfering ribose nucleic acid (siRNA) targeting molecule and application thereof | |
| CN107893115B (en) | ALKBH1 gene and application of expression product thereof in preparation of kit for diagnosing tumors and drugs for treating tumors | |
| CN101979553B (en) | siRNA molecule for interfering HBV gene and antiviral application thereof | |
| Shah et al. | HCC-Related lncRNAs: roles and mechanisms | |
| CN101979555B (en) | Small interference RNA molecule and application thereof | |
| WO2015085903A1 (en) | Non-coded rna of in-vivo infected microorganisms, parasitic microorganisms, symbiotic microorganisms and identification and application thereof | |
| CN102021170B (en) | Small interfering ribonucleic acid (siRNA) molecule of interfering hepatitis B virus gene and application thereof | |
| CN101979554B (en) | A kind of siRNA molecule and application thereof disturbing HBV gene | |
| CN101979557B (en) | SiRNA molecule and application thereof to antiviral medicaments | |
| CN101979558B (en) | A kind of siRNA molecule of target hepatitis B virogene and application thereof | |
| US10487328B2 (en) | Blocking Hepatitis C Virus infection associated liver tumor development with HCV-specific antisense RNA | |
| CN114246847B (en) | Application of chalcone compounds in treatment of coronavirus infection | |
| CN108707672A (en) | Applications of the DUXAP8 in diagnosis of hepatoma and treatment | |
| TWI414301B (en) | Treating picornavirus infection by targeting microrna mir-141 | |
| CN114246874B (en) | Use of ruscogenin in preventing coronavirus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| ASS | Succession or assignment of patent right |
Owner name: BENIT CO., LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20110617 Address after: 226016 Jiangsu city of Nantong Province Economic and Technological Development Zone No. 76 Chang Xing Lu Applicant after: Biomics Biotechnologies Co., Ltd. Co-applicant after: BENNETT CO., LTD. Address before: 226016 Jiangsu city of Nantong Province Economic and Technological Development Zone No. 76 Chang Xing Lu Applicant before: Biomics Biotechnologies Co., Ltd. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |